GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neovacs SA (STU:0LW) » Definitions » Gross Margin %

Neovacs (STU:0LW) Gross Margin % : 28.92% (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Neovacs Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Neovacs's Gross Profit for the six months ended in Jun. 2024 was €0.09 Mil. Neovacs's Revenue for the six months ended in Jun. 2024 was €0.33 Mil. Therefore, Neovacs's Gross Margin % for the quarter that ended in Jun. 2024 was 28.92%.


The historical rank and industry rank for Neovacs's Gross Margin % or its related term are showing as below:

STU:0LW' s Gross Margin % Range Over the Past 10 Years
Min: -28750   Med: -273.03   Max: 61.24
Current: 48.22


During the past 13 years, the highest Gross Margin % of Neovacs was 61.24%. The lowest was -28750.00%. And the median was -273.03%.

STU:0LW's Gross Margin % is ranked worse than
61.71% of 747 companies
in the Biotechnology industry
Industry Median: 60.58 vs STU:0LW: 48.22

Neovacs had a gross margin of 28.92% for the quarter that ended in Jun. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Neovacs was 0.00% per year.


Neovacs Gross Margin % Historical Data

The historical data trend for Neovacs's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovacs Gross Margin % Chart

Neovacs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -246.05 -300.00 -2,008.70 -28,750.00 5.62

Neovacs Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -639.22 508.16 -236.27 62.73 28.92

Competitive Comparison of Neovacs's Gross Margin %

For the Biotechnology subindustry, Neovacs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neovacs's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neovacs's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Neovacs's Gross Margin % falls into.



Neovacs Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Neovacs's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=0 / 0.534
=(Revenue - Cost of Goods Sold) / Revenue
=(0.534 - 0.504) / 0.534
=5.62 %

Neovacs's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=0.1 / 0.325
=(Revenue - Cost of Goods Sold) / Revenue
=(0.325 - 0.231) / 0.325
=28.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Neovacs  (STU:0LW) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Neovacs had a gross margin of 28.92% for the quarter that ended in Jun. 2024 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Neovacs Gross Margin % Related Terms

Thank you for viewing the detailed overview of Neovacs's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neovacs Business Description

Traded in Other Exchanges
Address
3-5, Impasse Reille, Paris, FRA, 75014
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.

Neovacs Headlines

No Headlines